The positive effects of anti-TNFα agents have previously been suggested based on laboratory data showing normalisation of thrombolytic characteristics in IBD patients responding to biologics.60 These data were supported by a study published by Detrez et al. 61. The gene discussed is TNF; the disease is inflammatory bowel disease.